Holen Sie sich die Stockscreener-App
86.77
0.44%
-0.38
Handel nachbörslich:
86.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RVTY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$87.15
Offen:
$87.27
24-Stunden-Volumen:
1.25M
Relative Volume:
1.02
Marktkapitalisierung:
$9.70B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$239.88M
KGV:
41.51
EPS:
2.0903
Netto-Cashflow:
$506.94M
1W Leistung:
-7.65%
1M Leistung:
-0.79%
6M Leistung:
-12.26%
1J Leistung:
-8.79%
1-Tages-Spanne:
$85.58
$88.12
1-Wochen-Bereich:
$82.79
$97.07
52-Wochen-Spanne:
$81.36
$118.30
Revvity Inc Stock (RVTY) Company Profile
Firmenname
Revvity Inc
Sektor
Branche
Telefon
781-663-6900
Adresse
77 4TH AVENUE, WALTHAM
Compare RVTY vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
86.77 | 9.70B | 2.86B | 239.88M | 506.94M | 2.0903 |
TMO
Thermo Fisher Scientific Inc
|
469.71 | 174.55B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
177.25 | 125.45B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
565.93 | 44.95B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.55 | 32.65B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
309.87 | 30.42B | 3.17B | 642.63M | 516.49M | 10.77 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-12-09 | Eingeleitet | Goldman | Neutral |
| 2025-10-16 | Eingeleitet | Guggenheim | Neutral |
| 2025-05-01 | Hochstufung | UBS | Neutral → Buy |
| 2025-01-10 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-07-08 | Eingeleitet | Leerink Partners | Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-23 | Fortgesetzt | Goldman | Buy |
Alle ansehen
Revvity Inc Aktie (RVTY) Neueste Nachrichten
Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’ - MSN
Revvity, Inc. Hits Day Low at $82.86 Amid Price Pressure - Markets Mojo
Revvity Inc. $RVTY Position Trimmed by Asset Management One Co. Ltd. - MarketBeat
Barclays downgrades Revvity (RVTY) - MSN
Is Now The Time To Look At Buying Revvity, Inc. (NYSE:RVTY)? - 富途牛牛
Revvity declares $0.07 dividend - MSN
Revvity expects to report Q4 revenue of $772 million - MSN
What to expect from Revvity's next quarterly earnings report - MSN
Is Revvity Inc (RVTY) a Bargain After 7.6% Drop? GF Value Says U - GuruFocus
Revvity (RVTY) slides as investors weigh softer growth profile and fresh analyst caution ahead of upcoming events - Quiver Quantitative
Revvity Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Revvity Drops 10.0% Amid Sector-Wide Selling - AlphaStreet
Revvity (NYSE:RVTY) Trading Down 9.7%What's Next? - MarketBeat
Why Revvity’s Stock Is Sinking Again Today - TipRanks
RVTY Revvity Inc. delivers 7.4 percent Q4 2025 EPS beat, shares climb 4.95 percent on upbeat investor sentiment.AI Stock Signals - UBND thành phố Hải Phòng
Roubaix Capital, LLC's Revvity Inc(RVTY) Holding History - GuruFocus
RVTY (Revvity Inc.) posts Q4 2025 EPS beat but dips slightly as investors react to muted year over year revenue growth.AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Insider Sell: Anita Gonzales Sells Shares of Revvity Inc (RVTY) - GuruFocus
Revvity (RVTY) VP Gonzales sells 80 shares under 10b5-1 trading plan - Stock Titan
Revvity Inc. stock (US76155R1086): Is life sciences growth strong enough to unlock new upside? - AD HOC NEWS
Installing Digital Tools at Calyxia With Revvity Signals: Accelerating the Transition from IP to Production - AZoM
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity Inc. stock (US76155R1086): Why does its life sciences focus matter more for U.S. investors n - AD HOC NEWS
Revvity Inc. stock (US76155R1086): Is its life sciences focus strong enough to drive steady investor - AD HOC NEWS
RVTY (NYSE: RVTY) proposes sale of 80 common shares in Form 144 notice - Stock Titan
A Look At Revvity (RVTY) Valuation As Mixed Recent Returns Contrast With Undervaluation Narrative - Yahoo Finance
Revvity, Inc. (RVTY) Stock Analysis: Navigating a 22.53% Upside Potential in the Healthcare Diagnostics Sector - DirectorsTalk Interviews
KBC Group NV Grows Stock Holdings in Revvity Inc. $RVTY - MarketBeat
The Bull Case For Revvity (RVTY) Could Change Following Its New AI-Enabled Oncology Platform Push - simplywall.st
Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know - Yahoo Finance
Revvity (NYSE:RVTY) Downgraded by Wall Street Zen to "Hold" - MarketBeat
Revvity Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Revvity Inc at Barclays Global Healthcare Conference Transcript - GuruFocus
Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026 - marketscreener.com
Assessing Revvity (RVTY) Valuation After Signals BioDesign Launch And Earnings Anticipation - Sahm
Revvity Inc (RVTY) Shares Fall 3.6% -- What GF Score of 79 Tells Investors - GuruFocus
Revvity, Inc.: - marketscreener.com
Revvity to Present at Upcoming Investor Conferences - Business Wire
Barclays Maintains Revvity(RVTY.US) With Hold Rating, Maintains Target Price $95 - Moomoo
Revvity (NYSE:RVTY) Lowered to Equal Weight Rating by Barclays - MarketBeat
RVTY Maintains Neutral Rating by Goldman Sachs -- Price Target L - GuruFocus
The Goldman Sachs Group Lowers Revvity (NYSE:RVTY) Price Target to $95.00 - MarketBeat
Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95 - Moomoo
Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118 - marketscreener.com
Massachusetts Financial Services Co. MA Has $106.19 Million Stake in Revvity Inc. $RVTY - MarketBeat
Finanzdaten der Revvity Inc-Aktie (RVTY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.42%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):